Microscopy & Imaging
Tackling Dementia with Cutting-Edge Brain Imaging Technology Stuart Gillespie, Digital Communications Offi cer, Dementias Platform UK. Email:
stuart.gillespie@
psych.ox.ac.uk
It’s one of the sad truths about dementia that by the time symptoms start to appear, it’s usually too late to reverse them. And as dementia grows into one of our most pressing public health issues, researchers urgently need the tools to help them detect the disorder in its earliest stages and develop effective treatments.
One of those tools – and one of the most valuable in the fi ght against dementia – is brain imaging technology. From detecting the build-up of toxic proteins in the brain, to learning more about how dementia takes hold at a cellular level, the deployment of magnetic resonance imaging (MRI) and positron emission tomography (PET) technologies can give scientists important insights into the development, progression and potential treatment of dementia.
Given PET-MR scanners are relatively new technology, their use in dementia research is not yet well understood. The harmonisation project run by Dr Matthews and colleagues will reduce the potential for variation between imaging sites and measure - in the words of the study protocol - the “repeatability and reproducibility” of testing across the UK as part of multi-centre DPUK cohort studies. Dr Matthews said: “Specifi cally, we need to understand the factors that result in variability in the measurements that we are making. Consequently, before using them in multi- centre clinical trials we need to harmonise how we use these scanners and once harmonised, measure the variability of the measurements.
“We have already conducted measurements on the scanners within the network using standard fi lled objects called ‘phantoms’. These results were presented at the recent IEEE medical imaging conference in Manchester. This exercise enables us to qualify all seven scanners in the network and have measurements on the similarities and differences in the performance of the scanners.
Dr Julian Matthews PET MR Scanner - credit University of Manchester
Critical to this research will be new network of state-of-the-art PET-MR scanners established by Dementias Platform UK (DPUK), a public-private partnership funded by the UK’s Medical Research Council that aims to speed up scientifi c advances in what has been a particularly stubborn area of research. The network of seven scanners, manufactured by Siemens and GE Healthcare and based at universities and hospitals across the UK, will build on existing brain imaging activities carried out under the auspices of DPUK.
Dr Julian Matthews, of the University of Manchester, is joint lead of the PET-MR project’s harmonisation phase and chief investigator of a clinical study that will ensure these high- specifi cation scanners are properly calibrated and providing consistent imaging results between sites. Dr Matthews said: “PET-MR is a new scanning technology which enables simultaneous acquisition of PET and MR data within a common scanning fi eld of view, with minimal interference between the two imaging modalities. In the UK there are seven such scanners, which are all part of the DPUK network, with an eighth scanner due to complete installation in Sheffi eld in the near future.
“We envisage that this unique national network will provide accurate imaging biomarkers and thus enable highly effective clinical studies in the UK of new therapeutics in neurodegenerative disease, including - but not limited to - dementia. Additionally, although not yet established, this equipment has many potential benefi ts, such as reducing the scanning burden to patients who require both PET and MRI scans as part of their care, as well as being used in research where the clinical state of patients can change between scanning sessions.”
“However, such phantom measurements are insuffi cient, as variations in human anatomy can affect the accuracy and precision of the measurements. To address this we plan to conduct a test-retest study where healthy elderly participants will have scans on two occasions. Some of the participants will be scanned twice at the same scanning site, but others will travel to a site with similar scanning equipment or, alternatively, with different scanning equipment. This will enable us to measure variability in these measurements and understand how much of the variability is due to the equipment being used, or the use of similar equipment at different sites,” Dr Matthews added.
Once the harmonisation study has been completed and the scanners deemed ready for deployment in clinical research, it is envisaged that the network will provide huge opportunities for delivering critical advances in dementia research. The homogenised network will enable unprecedented longitudinal population-based studies - much larger than previously possible - which, in combination with genetics, proteomics and clinical phenotyping, are expected to identify the pathophysiological mechanisms that determine disease initiation and progression.
It will also provide a platform for large-scale clinical trials to modify disease progression and – researchers hope – ultimately even prevent the progression of mild cognitive defi cits to dementia. Thus, the network of PET-MR scanners has enormous potential impact for the improvement of public health and reduction of the huge socio-economic costs associated with dementia.
The PET-MR scanners are part of DPUK’s broader imaging network, led by Professor Franklin Aigbirhio of the University of Cambridge. The network arose, he commented, from the recognition that advanced imaging has a central role to play in dementia research – and the feeling that a networked approach to imaging technology would greatly enhance the impact of the major research programmes already being run by a number of individual universities.
INTERNATIONAL LABMATE - FEBRUARY 2020
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88
